Nintedanib in children and adolescents with fibrosing interstitial lung disease: the InPedILD trial
R. Deterding (Aurora, CO, United States), L. Young (Philadelphia, PA, United States), E. Deboer (Aurora, CO, United States), D. Warburton (Los Angeles, CA, United States), S. Cunningham (Edinburgh, UK, United Kingdom), N. Schwerk (Hannover, Germany), K. Flaherty (Ann Arbor, MI, United States), K. Brown (Denver, CO, United States), M. Dumistracel (Ingelheim am Rhein, Germany), E. Erhardt (Biberach, Germany), J. Bertulis (Biberach, Germany), M. Gahlemann (Basel, Switzerland), S. Stowasser (Ingelheim am Rhein, Germany), M. Griese (Munich, Germany)
Source: International Congress 2022 – ALERT 3: COVID and interstitial lung diseases??
Session: ALERT 3: COVID and interstitial lung diseases??
Session type: Clinical trials session
Number: 2887
  
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Deterding (Aurora, CO, United States), L. Young (Philadelphia, PA, United States), E. Deboer (Aurora, CO, United States), D. Warburton (Los Angeles, CA, United States), S. Cunningham (Edinburgh, UK, United Kingdom), N. Schwerk (Hannover, Germany), K. Flaherty (Ann Arbor, MI, United States), K. Brown (Denver, CO, United States), M. Dumistracel (Ingelheim am Rhein, Germany), E. Erhardt (Biberach, Germany), J. Bertulis (Biberach, Germany), M. Gahlemann (Basel, Switzerland), S. Stowasser (Ingelheim am Rhein, Germany), M. Griese (Munich, Germany). Nintedanib in children and adolescents with fibrosing interstitial lung disease: the InPedILD trial. 2887
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|